Showing items 1 - 6 of 6

Your selections:

Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacists

Therapeutic drug monitoring in anticancer agents: perspectives of Australian medical oncologists

Patient and health care professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: a cross sectional survey.

A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing

Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping

Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites

  • 1
  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit